» Articles » PMID: 37409119

Novel MicroRNAs Modulating Ecto-5'-nucleotidase Expression

Overview
Journal Front Immunol
Date 2023 Jul 6
PMID 37409119
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The expression of immune checkpoint molecules (ICMs) by cancer cells is known to counteract tumor-reactive immune responses, thereby promoting tumor immune escape. For example, upregulated expression of ecto-5'-nucleotidase (NT5E), also designated as CD73, increases extracellular levels of immunosuppressive adenosine, which inhibits tumor attack by activated T cells. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level. Thus, the binding of miRNAs to the 3'-untranslated region of target mRNAs either blocks translation or induces degradation of the targeted mRNA. Cancer cells often exhibit aberrant miRNA expression profiles; hence, tumor-derived miRNAs have been used as biomarkers for early tumor detection.

Methods: In this study, we screened a human miRNA library and identified miRNAs affecting the expression of ICMs NT5E, ENTPD1, and CD274 in the human tumor cell lines SK-Mel-28 (melanoma) and MDA-MB-231 (breast cancer). Thereby, a set of potential tumor-suppressor miRNAs that decreased ICM expression in these cell lines was defined. Notably, this study also introduces a group of potential oncogenic miRNAs that cause increased ICM expression and presents the possible underlying mechanisms. The results of high-throughput screening of miRNAs affecting NT5E expression were validated in 12 cell lines of various tumor entities.

Results: As result, miR-1285-5p, miR-155-5p, and miR-3134 were found to be the most potent inhibitors of NT5E expression, while miR-134-3p, miR-6859-3p, miR-6514-3p, and miR-224-3p were identified as miRNAs that strongly enhanced NT5E expression levels.

Discussion: The miRNAs identified might have clinical relevance as potential therapeutic agents and biomarkers or therapeutic targets, respectively.

Citing Articles

MicroRNA-361-5p Alleviates Leydig Cell Apoptosis and Promotes Cell Growth by Targeting PIAS1 in Late-Onset Hypogonadism.

Zhou X, Ben C, Wu D, Xia A, Chang P, He B Mol Biotechnol. 2024; .

PMID: 38858301 DOI: 10.1007/s12033-024-01174-x.

References
1.
Li X, Wang S, Mu W, Barry J, Han A, Carpenter R . Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. J Exp Clin Cancer Res. 2022; 41(1):41. PMC: 8793215. DOI: 10.1186/s13046-022-02244-1. View

2.
Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

3.
Allard B, Pommey S, Smyth M, Stagg J . Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013; 19(20):5626-35. DOI: 10.1158/1078-0432.CCR-13-0545. View

4.
Melo S, Esteller M . Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2010; 585(13):2087-99. DOI: 10.1016/j.febslet.2010.08.009. View

5.
van Wijnen A, Bagheri L, Badreldin A, Larson A, Dudakovic A, Thaler R . Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development. Bone. 2020; 143:115659. DOI: 10.1016/j.bone.2020.115659. View